Castle Biosciences announced that on June 14, 2024, the Compensation Committee of its Board of Directors granted restricted stock units to 94 employees covering an aggregate of 158,197 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences publishes study on DecisionDx in SCC patients
- Castle Biosciences announces new data from DecisionDx-Um test study
- Castle Biosciences’ Growth at Risk: How Loan Terms Could Hamper Business Agility
- Castle Biosciences price target raised to $34 from $32 at Lake Street
- Castle Biosciences price target raised to $34 from $33 at Baird